Business · Companies · 12 hrs ago
Zambon targets more than €1 billion in revenue by 2030
Italian pharmaceutical group Zambon is aiming to pass €1 billion in revenue by 2030, up from €843 million in 2025.
The company, which marks its 120th anniversary this year, operates in 87 countries and has more than 2,770 employees.
Its 2026–2030 plan includes about €750 million in investment in research, facilities, technology and acquisitions.
Zambon is looking for medium-to-large biotech acquisitions in Europe and the United States, focused on rare diseases and the central nervous system.
It has reviewed 378 biotech companies over three years and reached due diligence with 16.
A possible US launch of an inhaled antibiotic to help prevent lung infections in people with a rare condition could add to growth, if approved by the FDA.
Zambon says it is working toward filing an authorization application by the end of 2027.
Zambon aims to exceed €1 billion in revenue by 2030, starting from €843 million in 2025.
The Italian pharmaceutical group plans to invest about €150 million a year, or €750 million over five years, in research, facilities, technology and acquisitions.
It is seeking medium-to-large acquisitions in rare diseases and the central nervous system in Europe and the United States.
The company says the revenue target is a minimum based on organic growth and could rise through acquisitions or new projects.
Zambon marked its 120th anniversary on November 11 and launched a six-pillar sustainability plan.
- Who
- Zambon, a pharmaceutical group led by president Elena Zambon.
- What
- It aims to exceed €1 billion in revenue by 2030 and plans investments and possible acquisitions to support growth.
- When
- The target is for 2030, under the company’s 2026–2030 industrial plan.
- Where
- Zambon operates in 87 countries and is seeking acquisitions in Europe and the United States.
- Why
- The company aims to grow its business, particularly in innovative therapies, including rare diseases and the central nervous system.
This story does not have two clearly opposing sides.
Pharmacist Gaetano Zambon founded the company with partner Silvio Farina.
A group of 240 Zambon employees and executives set out on the Camino de Santiago.
The group arrived at its destination after walking more than 70 kilometres.
Zambon officially celebrated its 120th anniversary and launched its One Health-ESG plan.
The company’s industrial plan sets out its revenue target and investment programme.
- Revenue in 2025
- €843 million
- Revenue target
- More than €1 billion by 2030
- Planned investment
- About €150 million per year; €750 million over five years
- Biotech companies reviewed
- 378 over three years
- Due diligence
- 16 biotech companies
- Company presence
- 87 countries and more than 2,770 employees
What people are saying
We have looked at 378 biotech companies over the last three years, and we reached due diligence with 16.
We are looking for medium-to-large acquisitions in rare diseases and the central nervous system, in Europe and the US.
How do I see this company in 2030? Increasingly international, strengthened in its three areas, and grown particularly in innovative therapies.